AUDITOR'S REPORT

AND

THE FINANCIAL STATEMENTS

OF

Silco Pharmaceuticals Limited

For the year ended June 30, 2026

PrimeGlobal | An Association of Independent Accounting Firms

FAMES & R
CHARTERED ACCOUNTANTS

Hossain Tower (11th Floor), 116 Naya Paltan, Box Culvert Road, Dhaka-1000
Cell: +88 01819 207889, 01819 496565, 01783 294818, 01713 008193, 01675 676963
E-mail: haque.fouzia@gmail.com, hoquezhc@yahoo.com, fmrashid@yahoo.com
shafi.selim1960@gmail.com, dishaarif4@gmail.com

INDEPENDENT AUDITORS' REPORT
TO THE SHAREHOLDERS OF
Silco Pharmaceuticals Limited
Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **Silco Pharmaceuticals Limited** (the "Company"), which comprise the Statement of Financial Position as at 30 June 2026 and Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements of the Company give a true and fair view of the financial position of the Company as at 30 June 2026, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) and other applicable laws and regulations.

Basis for Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Description of key audit matters	Our response to key audit matters
Valuation of Property, Plant and Equipment (PPE)	
The carrying value of the PPE amounted to BDT 1,568,351,908 as at 30 June 2026. The valuation of PPE was identified as a key audit matter due to the significance of this balance to the financial statements. Expenditures are capitalized if they create new or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the asset or its significant components will be used.	Our audit included the following procedures: • We reviewed the opening balances of PPE which was audited by us including assessed the addition during the year under our audit, checked the related accounting treatment and associated deferred tax as recognized by the company. • We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IFRS and found them to be consistent; • We obtained a listing of capital expenditures incurred during the year and, on a sample basis, checked whether the items were procured based on internal purchase order that had been properly approved by the responsible individuals;

The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.	• We inspected a sample of invoices and L/C documents to determine whether the classification between capital and operating expenditure was appropriate; • We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market price; • We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the classification from capital in progress to ready for use, with the date of the act of completion of the work. • We performed physical asset verification at the year end, observed procedures of asset acquisition, depreciation and disposal and finally assessed the appropriateness and presentation of disclosures as per relevant accounting standards. **[See note number 3.00 for details]**
Valuation of Inventory	
The Company had inventory of BDT 454,394,131 at 30th June 2026 which includes Finished Goods, Raw Materials, Work in Process, Packing Materials and Spare Parts. Inventory value is measured as follows: Inventories are stated at the lower of cost and net realizable value in accordance with IAS-2 'Inventories'. As result, the management apply judgment in determining the appropriate values for value in use, work-in-progress, values for slow moving or obsolete items and need to apply impairment provision.While excess holding of inventories could impact level of inventories can result in stock outs or irregular supply to the market.	We verified the appropriateness of management's assumptions applied in calculating the value of the inventory provisions by: • We evaluated the design and implementation c key inventory controls operating across the company's factory and warehouse; • We challenged the completeness of inventor provisions through assessing actual and forecast sales of inventory lines to assess whether provisions for slow-moving/obsolete stock are valid and complete. • We reviewed the historical accuracy of inventor provisioning and the level of inventory write- offs during the year; • We attended inventory counts and reconcilin the count results to the inventory listing to test the completeness of data; • We compared the net realizable value, obtaine through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories and comparison to the associated provision to assess whether inventory provisions are complete; • We discussed with management about the sales forecasting procedures and ordering of inventories, and inquired about remedial action taken in case of excess or shortage of inventories due to difference in forecast and actual results. **[See note number 6.00 for details]**

Measurement of Deferred Tax Liabilities	
The Company reported net deferred tax liabilities to totaling BDT as at 155,701,183. Significant judgment is required in relation to deferred tax liabilities as their recoverability is dependent on forecasts of future profitability over a number of years.	•We obtained an understanding, evaluated the design and tested the operational effectiveness of the company over the recognition and measurement and the assumptions used in estimating the future taxable income. • We also assessed the completeness and accurac of the data used for the estimations of future taxable income. • We involved our tax expertise to assess ke assumptions, controls, recognition and measurement of Taxes. • Finally, assessed the appropriateness an presentation of disclosure against IAS 12 Income Tax. **[See note number 15.00 for details]**
Revenue Recognition	
At year end the Company reported total revenue of BDT 372,149,751. Revenue is measured net of discounts, incentives and rebates earned by customers on the Company's sales. Within a number of the Company's markets, the estimation of discounts, incentives and rebates recognized based on sales made during the year is material and considered to be complex and judgmental. Therefore, there is a risk of revenue being misstated as a result of faulty estimations over discounts, incentives and rebates. There is also a risk that revenue may be overstated due to fraud through manipulation of the discounts, incentives and rebates recognized resulting from the pressure of local management may feel to achieve performance targets.	We have tested the design and operating effectiveness of key controls focusing on the following: •Calculation of discounts, incentives and rebates; • Segregation of duties in invoice creation an modification; and •Timing of revenue recognition. Our substantive procedures in relation to the revenue recognition comprises the following: • Obtaining supporting documentation for sale transactions recorded either side of year end as well as credit notes issued after the year end date to determine whether revenue was recognized in the correct period; • Within a number of the Company's market comparing current year rebate accruals to the prior year and, where relevant, completing further inquiries and testing. • Agreeing a sample of claims and rebate accru to supporting documentation; • Critically assessing manual journals posted t revenue to identify unusual or irregular items; and • Finally assessed the appropriateness an presentation of disclosure against relevant accounting standards. **[See note number 22.00 for details]**

Other information

Management is responsible for the other information. The other information comprises all of the information included in the Annual Report other than the financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditors' report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards (IFRSs) and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit in accordance with International Standards on Auditing (ISAs), we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the company's financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.
We have not come across any other key audit issue for the year under audit, and as such nothing is reportable.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act, 1994 and the Securities and Exchange Rules, 2020, we also report the following:

a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books;

c) the statement of financial position and statement of profit or loss and other comprehensive income together with the annexed notes dealt with by the report are in agreement with the books of account and returns; and

d) the expenditure incurred was for the purposes of the Company's business.

Sign for & on behalf of
FAMES & R
Chartered Accountants

Shafi Uddin Ahmed, FCA
Partner
Enrolment No. 0839
DVC#2610290839AS494949

Date: 29 October 2026
Place: Dhaka

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Silco Pharmaceuticals Limited
Statement of Financial Position
As at June 30, 2026

Particulars	Notes	Amount in Taka	
		30 June 2026	30 June 2025
Assets:			
Non Current Assets		**1,737,919,625**	**1,743,428,334**
Property, Plant and Equipment	**3.00**	1,568,351,908	1,601,488,059
Right of Use Assets	**4.00**	-	4,622,265
Capital Work-in-Progress	**5.00**	169,567,717	137,318,009
Current Assets		**1,033,113,387**	**1,017,294,468**
Inventories	**6.00**	454,394,131	450,669,140
Trade and Other Receivables	**7.00**	438,245,534	412,831,321
Advances, Deposits and Prepayments	**8.00**	122,953,674	127,532,684
Cash and Cash Equivalents	**9.00**	17,520,047	26,261,323
Investment In Share	**10.00**	-	-
Total Assets		**2,771,033,012**	**2,760,722,802**
Shareholder's Equity and Liabilities:			
Shareholder's Equity		**2,416,405,049**	**2,389,882,498**
Share Capital	**11.00**	1,038,070,000	1,038,070,000
Retained Earnings	**12.00**	1,378,335,049	1,351,812,498
Unrealized Gain/Loss on Marketable Securities	**13.00**	-	-
Non-Current Liabilities		**155,701,183**	**154,710,777**
Lease Liabilities (Non Current Portion)	**14.00**	-	-
Deferred Tax Liabilities	**15.00**	155,701,183	154,710,777
Current Liabilities		**198,926,780**	**216,129,528**
Trade and Other Payable	**16.00**	9,499,290	9,524,582
Lease Liabilities (Current Portion)		-	4,989,481
Payable to IPO Applicants	**17.00**	184,389	184,389
Provision for Expenses	**18.00**	5,233,792	6,604,819
Liabilities for contribution to WPPF	**19.00**	2,143,282	3,875,488
Dividend Payables (Unclaimed)	**20.00**	774,301	1,984,878
Provision for income tax	**21.00**	181,091,725	188,965,889
Total Liabilities		**354,627,963**	**370,840,304**
Total Shareholder's Equity and Liabilities		**2,771,033,012**	**2,760,722,802**
Net Asset Value (NAV) per Share	**30.00**	**23.28**	**23.02**

The annexed notes form an integral part of these financial statements.

Chairman **Managing Director** **Company Secretary**

Signed as per our separate report on same date.

Sign for & on behalf of
FAMES & R
Chartered Accountants

Shafi Uddin Ahmed, FCA
Partner
Enrolment No. 0839
DVC#2610290839AS494949

Date: 29 October 2026
Place: Dhaka

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Silco Pharmaceuticals Limited

Statement of Profit or Loss and other Comprehensive Income
For the year ended June 30, 2026

Particulars	Notes	Amount in Taka	
		2025-2026	2024-2025
Turnover	**22.00**	372,149,751	431,539,377
Less: Cost of Goods Sold	**23.00**	260,452,364	278,056,970
Gross Profit /(Loss)		**111,697,387**	**153,482,407**
Less: Operating Expenses	**24.00**	66,265,522	71,343,668
Profit from Operation		**45,431,864**	**82,138,739**
Less: Financial Expenses	**25.00**	186,360	105,335
Less: Financial Expenses (Lease)	**26.00**	236,579	648,155
Non-operation Income	**27.00**	724,041	521,547
Profit before Contribution to WPPF		**45,732,966**	**81,906,796**
Less: Workers' Profit Participation/Welfare Fund (WPPF)	**19.01**	2,143,282	3,875,488
Profit before Income Tax		**43,589,684**	**78,031,308**
Less: Provision for Income Tax	**28.00**	**9,676,054**	**35,384,010**
Current Tax	**28.01**	8,685,647	34,386,779
Deferred Tax	**28.02**	990,407	997,232
Net Profit/(Loss) after Tax (Transferred to Retained Earning)		**33,913,630**	**42,647,298**
Other Comprehensive Income:			
Unrealized Gain/(Loss) on Investment	**13.00**	-	1,148,297
Total Comprehenshive income		**33,913,630**	**43,795,595**
Earnings per Share (EPS)	**29.00**	**0.33**	**0.41**

The annexed notes form an integral part of these financial statements.

Chairman | **Managing Director** | **Company Secretary**

Signed as per our separate report on same date.

Sign for & on behalf of
FAMES & R
Chartered Accountants

Shafi Uddin Ahmed, FCA
Partner
Enrolment No. 0839
DVC#2610290839AS494949

Date: 29 October 2026
Place: Dhaka

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Silco Pharmaceuticals Limited
Statement of Changes in Equity
For the year ended June 30, 2026

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Amount in Taka
Balance as at July 01, 2025	1,038,070,000	-	1,351,812,498	2,389,882,498
Net Profit/(Loss) during the period	-	-	33,913,630	33,913,630
Declared 1.10% Cash Dividend	-	-	(7,391,079)	(7,391,079)
Unrealized Gain/(Loss) on Marketable Shares	-	-	-	-
Balance as on June 30, 2026	**1,038,070,000**	**-**	**1,378,335,049**	**2,416,405,049**

Silco Pharmaceuticals Limited
Statement of Changes in Equity
For the year ended June 30, 2025

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Amount in Taka
Balance as at July 01, 2024	1,038,070,000	(1,148,297)	1,315,518,065	2,352,439,767
Net Profit/(Loss) during the period	-	-	42,647,298	42,647,298
Declared 1% Cash Dividend			(6,352,863)	(6,352,863)
Unrealized Gain/Loss on Marketable Shares	-	1,148,297	-	1,148,297
Balance as on June 30, 2025	**1,038,070,000**	**-**	**1,351,812,498**	**2,389,882,498**

নাইম ফা(ওম)
Chairman

Managing Director

Company Secretary

Date: 29 October 2026
Place: Dhaka

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Silco Pharmaceuticals Limited
Statement of Cash Flows
For the year ended June 30, 2026

Particulars	Notes	Amount in Taka	
		2025-2026	2024-2025
A. Cash Flows from Operating Activities			
Cash received from Customers	**34.00**	346,735,538	438,302,485
Cash received from Non-operating income		724,041	1,451,270
Cash Paid to Suppliers	**35.00**	(147,509,683)	(162,343,345)
Cash Paid to Employees	**36.00**	(63,055,706)	(64,682,341)
Cash Paid to Others	**37.00**	(32,316,935)	(37,985,464)
Financial Expenses		(186,360)	(105,335)
Income Tax Paid		(15,564,185)	(97,339,825)
Net cash flows from operating activities		**88,826,710**	**77,297,445**
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		-	(1,170,680)
Cash Payment for Capital Work-in-Progress		(83,740,269)	(68,584,588)
Gain/(Loss) on Investment		-	(929,723)
Investment in Share		-	2,920,981
Net cash used in investing activities		**(83,740,269)**	**(67,764,010)**
C. Cash Flows from Financing Activities			
Refund to IPO Applicants (Bank Charge)		-	(104)
Financial Expenses (Lease)		(236,579)	(648,155)
Principle payment (Lease)		(4,989,481)	(4,577,905)
Cash dividend paid		(8,601,656)	(6,745,487)
Net Cash used for financing activities		**(13,827,716)**	**(11,971,651)**
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		**(8,741,276)**	**(2,438,216)**
E. Cash and Cash Equivalents at the beginning of the year		**26,261,323**	**28,699,542**
F. Cash and Cash Equivalents at the end of the year (D+E)		**17,520,047**	**26,261,323**
Net Operating Cash Flows Per Share (NOCFPS)	**31.00**	**0.86**	**0.74**

Chairman | **Managing Director** | **Company Secretary**

Date: 29 October 2026
Place: Dhaka

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

1.0 The Company and its operations

1.01 Legal form of the Company

The Company was incorporated in Bangladesh as Public Limited Company on January 25, 1995 as Company limited by Shares under the Companies Act 1994 vide registration no. C-27781(1627)/95. The principal activities of the Company are manufacturing drugs and medicines of all kinds. The Company obtained Certificate of Commencement of business at the same date of incorporation but the Company received its drug manufacturing license on 29th October, 2003 and the commercial operation started on 30th October, 2003. The company listed with Dhaka and Chittagong stock exchange on 25th April 2019 & 30th April 2019.

1.02 Address of the Registered Office

The registered office of the company is located at 41, Nurani, Bankalapara, Subid Bazar, Sylhet-3100, Bangladesh.

1.03 Nature of Business activities

Silco Pharmaceuticals limited has engaged in manufacturing, distribution and marketing of pharmaceuticals finished product in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Antipyretics, Anti In Flammatory Drugs, Anti ulcerants, Multi medicines which are sold in local market and in international markets respectively.

1.04 Capital Structure of the Company

Silco Pharmaceuticals Limited is a public limited company formed by local owner. The details of the capital structure are given below:

Particulars	Taka
Authorized Capital 105,000,000 ordinary shares of Taka 10/= each.	1,050,000,000
Issued, subscribed, called-up and paid-up capital 103,807,000 ordinary shares of Tk. 10/= each fully paid-up	1,038,070,000

1.05 Production Unit

The production unit of the company is situated at BSCIC industrial Estate, Khadimnagar, Sylhet 3103, Bangladesh.

2.00 Summary of significant accounting policies as per rules

2.01 Basis of preparation and presentation of the financial statements

The financial statements have been prepared on a going concern basis under historical cost convention and in accordance with the International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs), the Companies Act, 1994, the Securities and Exchange Rules, 2020 and other applicable laws & regulations in

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Bangladesh. The Financial Statements are presented in accordance with the guidelines provided by IAS-1 "Presentation of Financial Statements".

2.02 Regulatory Compliances

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

The Income Tax Act 2023;
The Value Added Tax and Supplementary Duty Act 2012;
The Value Added Tax and Supplementary Duty Rules 2016;
The Customs Act, 1969;
Bangladesh Labour Act 2006 (Amendment-2013);
The Securities and Exchange Ordinance, 1969;
The Securities and Exchange Rules, 2020; and
Financial Reporting Act 2015.

2.03 Accounting convention and assumption

The financial statements are prepared under the historical cost convention.

2.04 Principal accounting policies

The specific accounting policies have been selected and applied by the Company's management for significant transactions and events that have a material effect within the Framework of IAS-1 "Presentation of Financial Statements" in preparation and presentation of the financial statements. Financial Statements have been prepared and presented in compliance with applicable IAS and IFRS.

2.05 Application of Standards (IASs and IFRSs)

The following IASs and IFRSs are applicable for preparation of financial statements for the year ended 30 June 2026.

IASs:

IAS 1	Presentation of Financial Statements;
IAS 2	Inventories;
IAS 7	Statement of Cash Flows;
IAS-8	Accounting Policies, Changes in Accounting Estimates and Errors;
IAS 10	Events after the reporting Period;
IAS 12	Income Taxes;
IAS 16	Properties, Plant and Equipment;
IAS 19	Employee Benefits;
IAS 21	The Effects of Changes in Foreign Exchanges Rates;
IAS 23	Borrowing Costs;
IAS 24	Related Party Disclosures;
IAS 33	Earnings per Share;
IAS 36	Impairment of Assets;
IAS 37	Provisions, Contingent Liabilities and Contingent Assets;

IFRSs:

IFRS 1	First time Adoption of International Financial Reporting Standards;
IFRS 8	Operating Segments;
IFRS 9	Financial Instruments;

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

IFRS 13	Fair Value Measurement;
IFRS 15	Revenue from Contracts with Customers;
IFRS 16	Leases;

2.06 Use of Estimates and Judgments

The preparation of the financial statements requires management to make and apply consistently of judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates and underlying assumptions, which are reviewed on an ongoing basis. Revision to accounting estimates is recognized in the year in which the estimates are revised and in any future years affected.

2.07 Re-arrangement

Figures for the comparative year have been re-arranged wherever consider necessary to ensure better comparability with the current year presentation as per IAS-8 "Accounting policies, changes in Accounting estimates and Errors".

2.08 Going Concern

The company has adequate resources to continue in operation for foreseeable future and hence, the financial statements have been prepared on going concern basis. As per management assessment there is no material uncertainties related to event or condition which may cast significant doubt upon the company's ability to continue as a going concern.

2.09 Components of the Financial Statements

According to the IAS-1 "Presentation of Financial Statements" the complete set of financial statements includes the following components:

i) Statement of Financial Position as at June 30, 2026
ii) Statement of Profit or Loss and other Comprehensive Income for the year ended June 30, 2026;
iii) Statement of Changes in Equity for the year ended June 30, 2026;
iv) Statement of Cash Flows for the year ended June 30, 2026; and
v) Notes, comprising a summary of significant accounting policy and other explanatory information for the year ended June 30, 2026.

2.10 Property, Plant and Equipment (PPE)

i) **Recognition and Measurement**

In compliance with the IAS 16 "Property, Plant and Equipment" items of Property, Plant & Equipment (PPE) excluding Land and Land Development are initially measured at cost less accumulated depreciation, if any. Land and Land Development are measured at cost. The cost of an item of PPE comprises its purchase price, import duties and non-refundable taxes after deducting trade discount and rebates and any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable operating in the intended manner.

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

ii) Subsequent Cost

The cost of replacing part of an item of property, plant & equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the company and its cost can be measured reliably. The cost of the day to day maintaining cost on PPE is recognized in the Statement of Profit or Loss and Other Comprehensive Income as incurred.

iii) Depreciation

Depreciation has been charged on item of property, plant and equipment except land and land development is recognized in the statement of profit or loss and other comprehensive income using "Reducing Balance Method" over the estimated useful lives of each items. Depreciation on addition to fixed assets charged when the assets are available for use i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by the management.

Rate of depreciation on property, plant and equipment's considering their useful lives are as follows:

Category of Fixed Assets	As at 30 June, 2026	As at 30 June, 2025
Land and Land Development	-	-
Building	2.50%	2.50%
Plant & Machinery	10%	10%
Electrical Equipment	10%	10%
Electrical Installation	10%	10%
Furniture & Fixture	10%	10%
Office Equipment	10%	10%
Computer	20%	20%
Transformer	10%	10%
Vehicles	10%	10%
Air Condition	20%	20%
Fire Extinguisher	20%	20%

iv) **Retirement and Disposals:**

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of comprehensive income.

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

v) **Impairment:**
In accordance with the provision of IAS 36, the carrying amount of non-financial assets other than inventories of the company involved in the manufacturing of the products. If any such indication exists, then the asset's recoverable amount is estimated and impairment losses are recognized in the statement of comprehensive income. No such indication of impairment has been observed till the end of the year.

2.11 Valuation of Inventory
Inventories consisting of raw materials, work in process, finished goods are valued at lower of cost and net realizable value as per IAS 2: Inventory. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average cost formula. Where necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

2.12 Trade and Other Receivables
Trade Receivable is carried at net sales value by making no provision for doubtful debts, based on the risk from time to time. But in case of any debts made with any dissolved business house, the amount is fixed and charged with profit and loss account.

2.13 Cash and cash equivalents
Cash and cash equivalents include cash in hand, cash at banks, term deposits, etc which are available for use by the company without any restrictions. There is an insignificant risk of change in value of the same.

2.14 Creditors and accrued expenses

i) **Trade payables**
Liabilities are recorded at the amount payable for settlement in respect of goods and services received by the company.

ii) **Provision**
The preparation of financial statements in conformity with International Accounting Standard **IAS-37 "Provisions, Contingent Liabilities and Contingent Assets"** requires management to make estimates and Assumption that affect the reported amounts of revenues and expenses, assets and liabilities, and the Disclosure requirements for contingent assets and liabilities during and at the date of the financial statements.

In accordance with the guidelines as prescribed by IAS-37 provisions were recognized in the following situations when:

- The Company has a present obligation as a result of past event;
- It is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- When reliable estimates can be made of the amount of the obligation.

We have shown the provisions of the Financial Position at an appropriate level with regard to an adequate provision for risks and uncertainties. An amount recorded as a provision

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

represents the best estimate of the probable expenditure required to fulfill the current obligation on the date of statement of financial position.

2.15 Employee benefits

The company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19 Employee Benefits.

The cost of employee benefits is charged as revenue expenditure in the period to which the contributions relate.

The company's employee benefits include the following:

(a) Short-term employee benefits

Short-term employee benefits include salaries, bonuses, house rent, medical fees etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

(b) Contribution to Workers' Profit Participation/ Welfare Funds

The company provisions 5% of its profit from net business income to its Workers' Profit Participation Fund (WPPF) in accordance with Bangladesh Labour Act 2006 (Amendment-2013). The Company has registered the WPPF Trust deed and disbursed the provisioned amount accordingly.

The company made provision for WPPF in line with section 234 (a) chapter-XV (Workers 'participation in Companies Profits) of Bangladesh Labour Act-2006 and complied with section 234 (b). Transfer of the amount to a separate bank account is under process. The management of the company tried to disburse the amount to workers through banking channel but in fact, it was very hard to find a separate bank account of all the workers. Considering circumstance and requirement for compliance with chapter-XV section 234 (a) & (b) of Bangladesh Labour Act-2006,

It was hard for the management to ensure bank accounts of all workers who belongs to marginal class of the society. The payment of WPPF was made in cash. The company had also made the contribution to 'Bangladesh Labour welfare Foundation' through designated government as per requirement of Bangladesh Labour Act-2006.

2.16 Income Tax

i) **Current Tax**

Provision for taxation has been made as per rates prescribed in Finance Act 2026 and the Income Tax Act, 2023 on the profit made by the company.

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

ii) **Deferred Tax**

The company has recognized deferred tax in compliance with the provision of IAS-12: "Income Taxes". The policy of recognition of deferred tax assets/liabilities is based on temporary differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has been considered to determine net profit after tax. The rate prevailing at the Financial Position date is used for determine the deferred tax.

The company assumes no other temporary difference that may result in deferred tax asset/liability except Property, plant and Equipment.

2.17 VAT

Company's Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non-vatable items as per S.R.O No. 163-Law/2022/176-VAT, dated: June 01, 2022.

2.18 Contingent liabilities and assets

Contingent liabilities and assets are current or possible obligations or assets, arising from past events and whose existence is due to the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the company. In accordance with IAS-37 "Provisions, Contingent Liabilities and Contingent Assets" should not be recognized in the year in which the recognition criteria of provision have been made.

2.19 Revenue recognition

"As per IFRS-15: "Revenue from Contracts with Customers" an entity shall account for a contract with a customer only when all of the following criteria are met:

The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to performing their respective obligations;

a) The entity can identify each party 's rights regarding the goods or services to be transferred;

b) The entity can identify the payment terms for the goods or services to be transferred;

c) The contract has commercial substance (i.e. the risk, timing or amount of the entity's future cash flows is expected to change as a result of the contract); and

d) It is probable that the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer."

Considering the five steps model, the Company recognizes revenue at the time of delivery when (or as) the Company satisfies a performance obligation by transferring a promised good to a customer. Goods are considered as transferred when (or as) the customer obtains control of those goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

Sale of goods

The revenue from the sale of goods is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer when the buyer provides assurance on

the delivery of goods. The revenue represents the invoice value of goods supplied to the customers measured at the fair value of the consideration received or receivable.

2.20 Borrowing costs

In compliance with the requirements of IAS-23 "Borrowing Costs" borrowing costs of operational year on long term loan and short-term loan facilities from bank was charged off as revenue expenditure as they incurred.

2.21 Repairs, upkeep and maintenance charges

These are usually charged out as revenue expenditure in the year in which it is incurred.

2.22 Related party disclosure

The company in normal course of business carried out a number of transactions with related parties that fall within the definition of related party as prescribed by IAS-24 "Related Party Disclosures". This has been disclosed in a separate note to the financial statements.

2.23 Earnings per Share (EPS)

The Company calculates its Earning per Share (EPS) in accordance with ***IAS 33"Earnings per Share"*** which has been shown on the face of Statement of Comprehensive Income and the computation of EPS.

Basic Earnings

This represents earnings for the period attributable to the ordinary shareholders. As there are no preference dividends, minority interest or extra ordinary items, the net profit for the year has been considered as fully attributable to ordinary shareholders.

Basic Earnings Per Share

Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the company by the weighted average number of ordinary shares outstanding during the year.

Diluted Earnings per Share

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding, for the effect of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these Financial Statements as there were no potential ordinary shares during the relevant year.

Weighted Average Number of Ordinary Shares outstanding during the year

The basis of computation of number of shares in line with the provisions of IAS-33: Earnings per share. Therefore, the total number of shares outstanding at the year multiplied by a time-weighting factor which is the number of days the specific shares were outstanding as proportion of total number of days in the year.

2.24 Date of Authorization

The Board of Directors of **Silco Pharmaceuticals Limited** approved this Financial Statements on October 26, 2026.

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

2.25 Segment Reporting

As required by IFRS-8 "Operating Segments", if an entity operates and engages in different economic environments and activities then the entity has to disclose information, to enable users of its financial statements to evaluate the nature and financial effects of the business so carried out.

The company considers the operation on aggregate basis and manages the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

2.26 Statement of Cash flows

Statement of Cash Flows is prepared principally in accordance with IAS-7 "**Statement of Cash Flows**" and the cash flows from the operating activities have been presented under direct method as prescribed by the Securities and Exchange Rules 2020 and considering the provision of paragraph 19 of IAS-7 which provides that "Enterprises are Encouraged to Report Cash Flows from Operating Activities Using the Direct Method". We also provide cash flows from operating activities using the Indirect Method as well in notes to the Financial Statements.

2.27 Reporting period

The financial period of the Company covers 1 (one) year from 1st July 2025 to 30th June 2026.

2.28 Events after the Reporting period

In compliance with the requirements of IAS 10 Events after the Reporting Period that provide additional information about the company's position at the date of the financial position are reflected in the financial statements and events after the reporting period that are not adjusting events are disclosed in the notes when materials.

Management of the company has taken close look whether any events after the reporting period exist that need to take into account during the preparation of Financial Reports. No event after the reporting period exists and management of the company has prepared the financial reports in accordance.

2.29 Financial Risk Management Policies

The company is exposed to normal business risks from changes in market interest rates and currency exchange rates and from non-performance of contractual obligations by counterparties. The company does not hold or issue derivative financial instruments for speculative or trading purposes.

Interest Rate Risk

The company has no significant risk of fluctuations in interest rates.

Credit Risk

Credit risk is the potential financial loss resulting from the failure of a customer or counterparty to settle its financial and contractual obligations to the company as and when they fall due.

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. Credit evaluations are performed on all customers requiring credit over a certain amount. At the reporting date there were no significant concentrations of credit risk. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position. However, due to the large number of parties comprising the group's customer base, Management does not anticipate material losses from its debt collection.

Liquidity Risk

The company monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by management to finance the company operations and to mitigate the effects of fluctuations in cash flows.

Fair Values

The fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

The fair value of trade and other short-term receivables are taken to approximate their carrying value. The fair value of financial assets and liabilities approximate their carrying value.

2.30 Capital Work in Progress

Property, plant and equipment under construction/ acquisition are accounted for as capital work-in-progress until construction/ acquisition is complete and measured at cost. As the capital work in progress has not yet been finished and is not contributing to the production process to generate revenue, depreciation is not applied for capital work in progress as per Generally Accepted Accounting Principles (GAAPs- revenue and expense recognition principle).

2.31 Significant accounting policies

(i) Financial Instruments

At initial recognition as per IFRS-9 Financial Instrument, an entity shall measure a financial asset or financial liability as its fair value plus or minus (in the case of a financial asset or a financial liability not at fair value through profit or loss) the transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability.

After initial recognition (subsequent measurement) an entity shall measure a financial asset or financial liability in either of the following subject to specific circumstance specified in the standard (sec 4.1.1- 4.1.5) & (4.2.1-4.2.2):

i. amortized cost;
ii. fair value through other comprehensive income;
iii. fair value through profit or loss.

The entity shall recognize loss allowance or Expected Credit Loss (impairment requirement). At each reporting date the entity account for the impairment of financial assets or financial liability in the following manner:

I. an amount equal to the lifetime expected credit loss (if the credit risk of the instrument has increased significantly since initial recognition)
II. an amount equal to the 12 (twelve) month expected credit loss (if the credit risk of the instrument has not increased significantly since initial recognition)

FAMES & R. DHAKA BANGLADESH CHARTERED ACCOUNTANTS

(ii) Leases

An entity shall assess a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In line with IFRS-16 Leases, an entity shall determine the lease term as the non-cancellable period of a lease together with both:

I. Period covered by the option to extend the lease and;
II. Period covered by the option to terminate the lease.

Initial measurement of right of use asset shall be measured at cost and subsequently either by fair value or follow revaluation model.

The company disclosed the impact of IFRS-16 of numerical amount and disclosures in the financial statement in Annexure-B.

(iii) Insurance Contracts

IFRS 17 was issued in May 2017 and applies to annual reporting periods beginning on or after 1st January 2021.IFRS 17 established the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the standard. The objective of IFRS 17 is to ensure that an entity provides relevant information that faithfully represents those contracts.
The company has not yet assessed in potential impact of IFRS 17 on its financial statements.

2.32 Bad and Doubtful Debts

The Management recognized the bad and doubtful debts when a debt is unrecoverable through Board of Directors approved. Since, the management made sales through 100% confirms order by the customers and duly collected by the marketing team. Hence, no bad debts had occurred and therefore no provision was made against the receivables.

2.33 General

i. Wherever considered necessary, previous period's figures have been rearranged for the purpose of comparison.

Previous year's figure has been rearranged wherever considered necessary to confirm to current year's presentation

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Notes No.	Particulars	Notes	Amount in Taka	
			30 June 2026	30 June 2025
3.00	**Property, Plant and Equipment**			
	Opening balance		2,793,873,678	2,733,340,298
	Add: Addition during the year		51,490,561	60,533,380
	Closing balance		**2,845,364,239**	**2,793,873,678**
	Opening balance		1,192,385,619	1,103,356,852
	Add: Depreciation Charged for the year		84,626,712	89,028,767
	Closing balance		**1,277,012,331**	**1,192,385,619**
	Written Down Value as at June 30, 2026		**1,568,351,908**	**1,601,488,059**
	The details of above has been shown in **"Annexure- A"**			
4.00	**Right of Use Assets**			
	Opening balance		13,866,793	13,866,793
	Add: Addition during the year		-	-
	Less: Disposal during the year		-	-
	Closing balance		13,866,793	**13,866,793**
	Opening balance		9,244,528	4,622,264
	Add: Amortization/ Depreciation Charged for the year		4,622,265	4,622,264
	Less: Disposal during the year			-
	Closing balance		**13,866,793**	**9,244,528**
	Written Down Value as at June 30, 2026		**-**	**4,622,265**
	The details of above has been shown in **"Annexure- B"**			
5.00	**Capital Work-in -Progress**			
	Construction of Building	5.01	99,782,275	102,380,514
	Plant and Machinery	5.02	69,785,442	34,937,495
	Total		**169,567,717**	**137,318,009**
5.01	**Construction of Building**			
	Opening balance		102,380,514	74,207,645
	Add: Addition during the year		38,950,360	55,879,983
			141,330,874	**130,087,628**
	Less: Transfer to fixed assets during the year		41,548,599	27,707,114
	Closing balance		**99,782,275**	**102,380,514**
5.02	**Plant and Machinery**			
	Opening balance		**34,937,495**	53,888,476
	Add: Addition during the year		44,789,909	12,704,605
			79,727,404	**66,593,081**
	Less: Transfer to fixed assets during the year		9,941,962	31,655,586
	Closing balance		**69,785,442**	**34,937,495**
6.00	**Inventories**			
	Raw Materials	23.01	196,305,551	194,574,588
	Packaging Materials	23.02	16,027,460	17,139,019
	Work in Process	23.00	9,513,256	9,659,472
	Finished Goods	23.00	226,656,916	223,395,612
	Store Items	23.03.01	5,890,948	5,900,449
	Total		**454,394,131**	**450,669,140**
7.00	**Trade and Other Receivables**			
	Trade Receivables		438,245,534	412,831,321
	Total		**438,245,534**	**412,831,321**

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Notes No.	Particulars	Notes	Amount in Taka	
			30 June 2026	30 June 2025
	Ageing of the above Trade Receivable is given below:			
	Less than twelve months		95,587,215	85,585,452
	Less than six months		342,658,319	327,245,869
	Total		**438,245,534**	**412,831,321**

The classification of receivables as required by the schedule XI of the Companies Act, 1994 are given below:

i. Receivables considered good in respect of which the company is fully secured		
ii. Receivables considered good in respect of which the company holds no security other than the debtor personal security	438,245,534	412,831,321
iii. Receivables considered doubtful or bad		
iv. Advance, deposits & prepayment due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, deposits & prepayment due by firms or private companies respectively in which any director is a partner or a director or a member		
v. Receivables due from companies under same management		
vi. The maximum amount of receivable due by any director or other officer of the company		

8.00	**Advances, Deposits and Prepayments**			
	Advances	8.01	121,376,847	125,370,857
	Deposits	8.02	1,576,827	1,576,827
	Prepayments	8.03	-	585,000
	Total		**122,953,674**	**127,532,684**
8.01	**Advances**			
	Advance to Employees		459,270	640,800
	Advance to Suppliers		75,012,245	75,928,648
	Advance Income Tax	08.01.01	43,608,446	44,604,073
	L/C Margin		1,910,318	-
	VAT Closing balance		386,569	4,197,337
	Total		**121,376,847**	**125,370,857**
08.01.01	**Advance Income Tax (AIT)**			
	Opening balance		44,604,073	77,878,296
	Add: AIT Paid during the year		8,530,471	9,526,098
			53,134,544	87,404,394
	Less: AIT Adjustment againts provision (For Ass.year 2025-2026)		(9,526,098)	(42,800,321)
	Closing balance		**43,608,446**	**44,604,073**
8.02	**Security Deposit**			
	Electricity (Power Development Board)		317,400	317,400
	Gas (Jalalabad Gas Distribution Company Ltd.)		1,259,427	1,259,427
	Total		**1,576,827**	**1,576,827**
8.03	**Prepayments**			
	Office Rent			585,000
	Total		**-**	**585,000**

Notes No.	Particulars	Notes	Amount in Taka	
			30 June 2026	30 June 2025
9.00	**Cash and Cash Equivalent**			
	Cash in hand		13,177,857	13,521,064
	Cash at Bank	9.01	4,342,190	12,740,259
	Total		**17,520,047**	**26,261,323**
9.01	**Cash at Bank**			
	Cash at Bank	09.01.01	4,122,502	12,520,251
	IPO Fund	09.01.02	217,435	217,455
	Balance of Portfolio	09.01.03	2,253	2,553
	Total		**4,342,190**	**12,740,259**
09.01.01	**Cash at Bank**			
	Bank Asia CD # 01033005988		1,450,590	4,567,184
	City Bank Ltd., CD-3102434003001		795,532	1,976,680
	Bank Asia CD # 01036000766		2	2
	Pubali Bank Ltd., A/C No. C/D-2836901017223		683,765	341,077
	AB Bank Ltd., A/C No. C/D-4111-043420-000		161,453	88,348
	DBBL, A/C No. C/D-201.110.6703		72,311	212,884
	DBBL, A/C No. C/D-1881		36,607	26,773
	DBBL, A/C No. C/D-1154		8,985	152,985
	Pubali Bank Ltd., A/C No. C/D-3486901021357		321,505	243,002
	Prime Bank Ltd., A/C No. C/D-80025295/3115312009636		19,022	947,242
	Prime Bank Ltd., A/C No. C/D-60020426/3115111005507		409,629	3,962,434
	Standard bank Ltd. A/c-4387		37,981	-
	Al-Arafah Islami Bank A/c-20897		125,121	1,641
	Total		**4,122,502**	**12,520,251**
09.01.02	**IPO Fund**			
	EBL_ Principal Branch _BDT_A/C_1011360531186		33,046	33,066
	EBL_ Principal Branch_USD_A/C_1013050531221		149,880	149,880
	EBL_ Principal Branch_EURO_A/C_1013070531196		34,509	34,509
	Total:		**217,435**	**217,455**
09.01.03	**Balance of Portfolio**			
	AB Scurities Ltd.-Portfolio Code 08348		986	1,136
	City Brokerage Ltd.-Portfolio Code C12003		1,268	1,418
	Total		**2,253**	**2,553**
10.00	**Investment In Share**			
	Total		**-**	**-**

The Company recognised its investment considering fare value i. e. market value on 30 June 2026.

11.00	**Share Capital**		
11.01	**Authorized Share Capital**		
	105,000,000 ordinary shares of Tk. 10/= each.	**1,050,000,000**	**1,050,000,000**
11.02	**Issued, Subscribed and Paid-up Share Capital**		
	103,807,000 ordinary shares of Tk. 10/= each fully paid-up	1,038,070,000	1,038,070,000
		1,038,070,000	**1,038,070,000**

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Notes No.	Particulars	Notes	Amount in Taka	
			30 June 2026	30 June 2025

The shareholding position at the end of the year as on June 30, 2026 are shown below:

Category of Shareholders	No. of Ordinary Shares Held	Percentage (%) of Paid-up Capital
Directors, sponsor's & promoters	36,615,370	35.27%
Government	-	
Institution	20,408,297	19.66%
Foreign	-	
General Public	46,783,333	45.07%
Total	**103,807,000**	**100.00%**

12.00 Retained Earnings

Opening balance	1,351,812,498	1,315,518,064
Add: Profit during the year	33,913,630	42,647,298
	1,385,726,128	**1,358,165,361**
Less: Cash Dividend @1.10% for the year (2024-2025)	(7,391,079)	(6,352,863)
Closing Balance	**1,378,335,049**	**1,351,812,498**

13.00 Unrealized Gain/Loss on Marketable Securities

Opening balance	-	(1,148,297)
Add: Unrealized Gain/Loss on Marketable Shares	-	1,148,297
Closing Balance	-	-

14.00 Lease Liabilities

Opening balance	4,989,481	9,567,386
Add: Addition during the year (Principle)		-
Add: Addition during the year (Interest)	236,579	648,155
Less: Paid during the year	(5,226,060)	(5,226,060)
Closing balance	-	**4,989,481**
Less: Curent Portion	-	4,989,481
Non- Current Portion	-	-

15.00 Deferred Tax Liabilities

WDV as Accounting base (PPE)	1,568,351,908	1,601,488,059
WDV as Accounting base (ROU)		4,622,264
WDV as per Tax base (PPE)	(876,346,649)	(914,102,390)
Lease Obligation*	-	(4,404,481)
Temporary Difference	**692,005,260**	**687,603,452**
Applicable Tax Rate	22.50%	22.50%
Deferred Tax Closing Balance	**155,701,183**	**154,710,777**

***Lease Obligation**

Lease Liability as on June 30, 2026		4,989,481
Less: Advance		(585,000)
Total	-	**4,404,481**

16.00 Trade and Other Payables

Trade Payables	9,499,290	9,524,582
Total	**9,499,290**	**9,524,582**

17.00 Payable to IPO Applicants

EBL_ Principal Branch_USD_A/C_1013050531221	149,880	149,880
EBL_ Principal Branch_EURO_A/C_1013070531196	34,509	34,509
Total	**184,389**	**184,389**

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Notes No.	Particulars	Notes	Amount in Taka	
			30 June 2026	30 June 2025
18.00	**Provision for Expenses**			
	Electricity, Gas, telephone, Water & other Bills		342,655	282,749
	Salary & Wages allowance		4,376,137	5,862,070
	Director Remuneration		100,000	45,000
	Others		65,000	65,000
	Audit Fees (Including VAT)		350,000	350,000
	Total		**5,233,792**	**6,604,819**
19.00	**Liabilities for contribution to WPPF**			
	Opening balance		3,875,488	2,906,798
	Add: Addition during the year	19.01	2,143,282	3,875,488
	Available for contribution to WPPF		**6,018,770**	**6,782,286**
	Less: Paid during the year		3,875,488	2,906,798
	Closing balance		**2,143,282**	**3,875,488**
19.01	**Provision for WPPF during the year**			
	Profit before Contribution to WPPF		45,732,966	81,906,796
	Less: Non-operation Income (Net)	27.00	724,041	521,547
			45,008,925	**81,385,249**
	Provision during the year		**2,143,282**	**3,875,488**
20.00	**Dividend Payables (Unclaimed)**			
	Opening balance		1,984,878	2,377,502
	Add: Addition during the year		7,391,079	6,352,863
			9,375,957	**8,730,365**
	Less: Paid during the year		8,601,656	6,745,487
	Closing balance		**774,301**	**1,984,878**
21.00	**Provision for income tax**			
	Opening balance		188,965,889	285,193,159
	Add: Charge for the year	28.01	8,685,647	34,386,779
			197,651,537	319,579,937
	Less: Tax adjustment and paid (For Ass. Year 2025-2026)		16,559,812	
	Less: Tax adjustment againts AIT (For Ass. Year 2019-2020 to 2024-2025)		-	42,800,321
	Less: Tax paid with return (For Ass. Year 2019-2020 to 2024-2025)		-	87,813,727
	Closing balance		**181,091,725**	**188,965,889**

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025
22.00	**Turnover**			
	Sales		372,149,751	431,539,377
23.00	**Cost of Goods Sold**			
	Raw materials consumed	23.01	111,033,190	116,507,644
	Packaging materials consumed	23.02	36,150,302	39,423,925
	Total materials consumption		**147,183,492**	**155,931,569**
	Add: Work in process-opening		9,659,472	9,591,022
	Less: Work in process-closing		9,513,256	9,659,472
	Total consumption		**147,329,708**	**155,863,119**
	Add: Factory overhead	23.03	117,404,418	126,573,626
	Cost of production		**264,734,126**	**282,436,745**
	Add: Finished goods-opening		223,395,612	220,525,748
	Production available for Sales		**488,129,738**	**502,962,493**
	Less: Finished goods-closing		226,656,916	223,395,612
	Less: Sample Expenses		1,020,458	1,509,911
	Cost of Goods Sold		**260,452,364**	**278,056,970**
23.01	**Raw materials consumed**			
	Opening Stock		194,574,588	193,065,890
	Add: Purchase during the year		112,764,153	118,016,342
	Raw materials available for production		**307,338,741**	**311,082,232**
	Less: Closing Stock		196,305,551	194,574,588
	Total		**111,033,190**	**116,507,644**
23.02	**Packaging Materials Consumed**			
	Opening Stock		17,139,019	14,958,695
	Add: Purchase during the year		35,038,743	41,604,249
	Consumable Item available for packaging		**52,177,762**	**56,562,944**
	Less: Closing Stock		16,027,460	17,139,019
	Total		**36,150,302**	**39,423,925**
23.03	**Factory Overhead**			
	Salary, Wages & Allowance		20,510,880	22,353,853
	Medical Expenses		342,560	340,200
	Food & Tiffin		88,362	96,000
	Labor Charge		996,540	1,396,039
	Research & Development		390,550	397,800
	Carrying Charge		1,689,575	2,040,240
	Fuel, Oil & Lubricant		5,152,085	7,455,852
	Postage, Telephone, Mobile & Fax		173,670	201,359
	Printing, Stationary & Carton		1,225,955	1,356,259
	Repairs & Maintenance		956,445	1,042,882
	Electricity, Gas & Water Bills		3,208,453	3,050,341
	Store items	23.03.01	2,507,850	2,525,846
	Internet expenses		30,240	
	Other Overhead		582,144	629,914
	Depreciation (Annexure-A)		79,549,109	83,687,041
	Total		**117,404,418**	**126,573,626**

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025
23.03.01	**Store Items**			
	Opening balance		5,900,449	5,954,498
	Add: Purchase during the year		2,498,349	2,471,797
			8,398,798	**8,426,295**
	Less: Consumption during the year		2,507,850	2,525,846
	Closing balance		**5,890,948**	**5,900,449**
24.00	**Operating Expenses**			
	Administrative Expenses	24.01	20,283,322	21,708,381
	Selling & Distribution Expenses	24.02	45,982,200	49,635,287
	Total		**66,265,522**	**71,343,668**
24.01	**Administrative Expenses**			
	Salary & Allowances		12,357,294	13,533,216
	Director Remuneration (MD)		815,000	540,000
	Postage, Telephone, Fax & Mobile bill		94,784	99,953
	Traveling & Conveyance Expenses		174,555	205,169
	Repair & Maintenance		197,755	286,300
	Electricity, Gas, Fuel & Water bill		320,769	441,294
	Printing, Stationery & Carton		278,208	336,735
	Subscriptions & Donation		45,500	45,000
	Entertainment Expenses		123,302	126,351
	Training Expense		65,280	71,823
	Audit fees including Vat		350,000	350,000
	Miscellaneous Expenses		32,015	30,250
	Photocopy , Newspaper & Periodical Expenses		43,662	50,630
	Internet expenses		124,303	-
	Annual fees & AGM Expenses		1,185,228	1,243,888
	Legal & Professional fees		325,450	474,373
	Fees & Renewal		338,284	373,425
	Depreciation (Annexure-A)		1,692,534	1,780,575
	Depreciation (Annexure-B-ROU)		1,719,399	1,719,399
	Total		**20,283,322**	**21,708,381**
24.02	**Selling & Distribution Expenses**			
	Salary & Allowance		28,123,129	28,743,377
	Transportation, TA & DA and Handling Expenses		4,239,435	4,592,050
	Repair and Maintenance		128,980	153,055
	Food Allowance		240,506	247,179
	Delivery Expenses		917,171	1,261,292
	Advertisement Expenses		78,243	183,153
	Postage, Telephone, Mobile & Fax bill		468,790	540,853
	Electricity,Water, Gas & Fuel bill		668,939	821,200
	Sales Promotion Expenses		2,325,235	3,267,169
	Travelling & Conveyance Expenses		454,316	629,896
	Entertainment Expenses		291,766	327,781
	Training Expense		325,400	427,705
	Samples Expenses		1,020,458	1,509,911
	Printing & Stationery		224,418	254,940
	Miscellaneous Expenses		187,480	211,711
	Depreciation (Annexure-A)		3,385,068	3,561,151
	Depreciation (Annexure-B-ROU)		2,902,866	2,902,866
	Total		**45,982,200**	**49,635,287**

Notes No.	Particulars	Notes	Amount in Taka 2025-2026	Amount in Taka 2024-2025
25.00	**Financial Expenses**			
	Bank Charges		186,360	105,335
	Total		**186,360**	**105,335**
26.00	**Financial Expenses (Lease)**			
	Lease Expenses		236,579	648,155
	Total		**236,579**	**648,155**
27.00	**Non-operating Income**			
	Interest Income on Bank		28,551	38,510
	Realized Gain/(Loss) on Sale of Share (net)		-	(929,723)
	Sales of Wastage		595,490	870,160
	Dividend Income		-	-
	Sale of Sand		100,000	542,600
	Total		**724,041**	**521,547**
28.00	**Income Tax Expenses**			
	Current Tax	28.01	8,685,647	34,386,779
	Deferred Tax	28.02	990,407	997,232
	Total		**9,676,054**	**35,384,010**
28.01	**Current Tax**			
	A. Corporate Tax			
	Profit before Tax		43,589,684	78,031,308
	Less: Dividend Income		-	-
	Business income including other income		**43,589,684**	**78,031,308**
	Add: Depreciation as Accounting base		84,626,712	89,028,767
	Add: Interest on Lease		236,579	648,155
	Add: Depreciation as Accounting base (ROU Assets)		4,622,265	4,622,264
	Sub-total:		**133,075,240**	**172,330,494**
	Less: Depreciation as per Tax base		(89,246,302)	(93,505,267)
	Less: Lease Payment		(5,226,060)	(5,226,060)
	Taxable Profit/ Net business income		**38,602,878**	**73,599,167**
	Income Tax Rate		22.5%	22.50%
	Current Tax for business income		**8,685,647**	**16,559,813**
	Tax from Dividend Income @ 20%			-
	Total current tax		**8,685,647**	**16,559,813**
	Add: Short Provision for the Ass. Years 2019-2020 to 2024 -2025		-	17,826,966
			8,685,647	**34,386,779**
	Minimum tax Calculation			
	Calculation of Gross Receipts			
	Turnover		372,149,751	431,539,377
	Non-Operating Income		724,041	521,547
	Total Gross Receipts		**372,873,792**	**432,060,924**
	Minimum tax rate (1% on total gross receipts)		**3,728,738**	**4,320,609**
	Tax deducted at source		**8,530,471**	**9,526,098**
	Income Tax Provision whichever is higher		**8,685,647**	**16,559,813**

Income tax provision is higher between tax at corporate rate on income, Tax deducted at

Source and minimum tax on gross receipts U/S 163 sub-section 6 of Income Tax Act 2023.

Hence tax at corporate rate is accounted for as it is higher than the minimum tax .

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025
28.02	**Deferred Tax**			
	Deferred Tax Liability Closing	15.00	155,701,183	154,710,777
	Deferred Tax Liability Opening		154,710,777	153,713,545
	Deferred Tax Expenses/(Income) during the year		**990,407**	**997,232**
29.00	**Earnings Per Share (EPS)**			
	a) Net Profit after Tax		33,913,630	42,647,298
	b) Total Number of Shares outstanding		103,807,000	103,807,000
	Earnings Per Share (EPS) (a/b)		**0.33**	**0.41**
30.00	**Net Asset Value (NAV) Per Share**			
	Total Assets		2,771,033,012	2,760,722,802
	Less: Total Liabilities		354,627,963	370,840,304
	A. Net Asset Value (NAV)		**2,416,405,049**	**2,389,882,498**
	B. Total Number of Share outstanding		103,807,000	103,807,000
	Net Asset Value (NAV) Per Share (A/B)		**23.28**	**23.02**
31.00	**Net operating cash flow per share (NOCFPS)**			
	a) Net Operating Cash Flows		88,826,710	77,297,445
	b) Weighted average number of shares outstanding		103,807,000	103,807,000
	Net operating cash flow per share (NOCFPS) (a/b)		**0.86**	**0.74**

31.01 Reconciliation of Net Income or Net Profit with Cash Flows from Operating Activities (Indirect Method) the requirement of Bangladesh Securities and Exchange Commission notification no. BSEC/CMRRCD/2006-158/308/Admin/81, Dated 08 August 2018.

Particulars	Amount in taka	
	30 June 2026	30 June 2025
Net Profit before Tax	43,589,684	78,031,308
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation on Fixed Assets & ROU	89,248,977	93,651,031
Unrealized Foreign Exchange Gain/Loss		
Interst on lease	236,579	648,155
Realized Gain/(Loss) on Sale of Share		
Gain/ Loss on Investment		929,723
(Increase)/Decrease in Inventories	(3,724,991)	(6,573,287)
(Increase)/ Decrease in Trade Receivables	(25,414,214)	6,763,108
FDR Interest Receivable		
(Increase) /Decrease in Advance, Deposits and Prepayments	3,583,383	(32,673)
Increase /(Decrease) in provision for expenses	(1,371,027)	331,499
Increase/(Decrease) in Liabilities for WPPF	(1,732,206)	968,690
Increase/ (Decrease) in Trade Payables	(25,292)	(80,283)
Income tax paid	(15,564,185)	(97,339,825)
Net Cash Generated from Operating Activities	**88,826,710**	**77,297,445**
Net Cash Generated from Operation Activities (direct Method)	**88,826,710**	**77,297,445**
Difference	**Nil**	**Nil**

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025

32.00 Information as per the Companies Act, 1994. -

32.01 Disclosures as per IAS 24 Related Party disclosures are as follows:

During the period the company carried out a number of transations with related parties in the normal course of business on as arms'length basis. Name of those related parties, nature of those transaction and thire total value have been set out in accordance with the provisions of IAS-24: Related party disclosures.

Remuneration:

Name of Directors	Designation	Outstanding as on June 30, 2026	Outstanding as on June 30, 2025
Dr. Md. Badrul Haque Rukan	Managing Director	100,000	45,000

As per Para-17, IAS-24:
An entity shall disclose key management personnel compensation in total and for each of the following benefits;

(a) Short-term employee benefits	815,000	540,000
(b) Post-employee benefits	Nil	Nil
(c) Other long term benefits	Nil	Nil
(d) Termination benefits and	Nil	Nil
(e) Share-based payment	Nil	Nil

As per Para-18, IAS-24

Disclosure requirments of IAS 24 Para 18 minimum disclosure shall include:

a) The amount of transaction	815,000	540,000
b) Tahe amount of outstanding balance, including commitments	100,000	45,000
i) Their terms & condition, including whether they are secured, and the nature of the consideration to be provided in settlement.	Remuneration	Remuneration
ii) detaisl of any guarantee given or received.	Nil	Nil
c) Provision for doubtful debts related to the amount of outstanding balance.	Nil	Nil
d) The expenses recognized during the period in respect of bad or doubtful debts due from related parties.	Nil	Nil

32.02 Disclosure as per requirement of Schedule XI, part II, Para 4 of the

a) Managerial Remuneration paid or payable during the financial period to the directors, including managing directors, a managing agent or manager;	815,000	540,000
b) Expenses reimbursed to the Managing Agent;	Nil	Nil
c) Commission or Remuneration payable separately to a managing agent or his associate;	Nil	Nil
d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.;	Nil	Nil
e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year.;	Nil	Nil

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025
	f) Any other perquisite or benefits in cash or in kind stating, approximate money value where practicable ;		Nil	Nil
	g) Other allowances and commission including guarantee commission; pensions etc.:		Nil	Nil
	(i) Pensions		Nil	Nil
	(ii) Gratuities		Nil	Nil
	(iii) Payments from a provident funds, in excess of own subscription and interest thereon		Nil	Nil
	(iv) Compensation for loss of office		Nil	Nil
	(v) Consideration in connection with retirement from office.		Nil	Nil

32.03 Aggregated amount of remunerating paid to all Directors and Officers

Particulars	Nature of Payment		Amount in Tk
Managing Director	Remuneration	815,000	540,000
Officers and Executives	Salary and other Allowances	12,357,294	13,533,216
Total		**13,172,294**	**14,073,216**

33.00 Board Meeting attendance Fees

Board of Directors of Silco Pharmaceuticals Limited till now have not taken any board meeting attendance fees. During the period from 01.07.2025 to 30.06.2026, there were 07 (Seven) Board Meeting held. The attendance status of the meeting is as follows:

Name of Board of Directors	Designation	Number of Meeting Held	Number of Meeting Attending
Mrs.Naim Fatema	Chairman	7	7
Dr. Md Badrul Haque Rukan	Managing Director	7	7
Rowshan Ara Chowdhury	Director	7	4
Dr. Gulshan-E-Jahan	Director	7	6
Prof. Dr. Md. Harunur Rashid	Director	7	7
Dr. Mahmudul Majid Chowdhury	Director	7	6
Prof. Dr. Faisal Ahmed	Director	7	7
Dr. Sultana Aziz	Independent Director	7	7
Dr. Shamim Ahmed	Independent Director	7	7

34.00 Received from Customers

Sales during the year	372,149,751	431,539,377
Add: Opening Receivables	412,831,321	419,594,428
Less: Closing Receivables	438,245,534	412,831,321
Total	**346,735,538**	**438,302,485**

35.00 Paid to Suppliers

Purchase during the year	150,301,245	162,092,388
Add: Opening Trade Payables	9,524,582	9,604,865
Less: Closing Trade Payables	9,499,290	9,524,582
Add: Closing Advance to Supplier	77,309,131	80,125,984
Less: Opening Advance to Supplier	80,125,984	79,955,311
Total	**147,509,683**	**162,343,345**

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Notes No.	Particulars	Notes	Amount in Taka	
			2025-2026	2024-2025
36.00	**Paid to Employees**			
	Salary, Wages Including Bonus		61,806,303	65,170,446
	Add: Opening wages & Remuneration Payables		5,907,070	5,556,965
	Less: Closing wages & Remuneration Payables		4,476,137	5,907,070
	Add: Closing Advance to Employee		459,270	640,800
	Less: Opening Advance to Employee		640,800	778,800
	Total		**63,055,706**	**64,682,341**
37.00	**Paid to Others**			
	Factory Overhead		94,385,688	101,693,927
	Administrative Expenses		7,111,028	7,635,165
	Selling Expenses		17,859,071	20,891,910
	WPPF during the year		2,143,282	3,875,488
	Add: Opening WPPF Payables		3,875,488	2,906,798
	Less: Closing WPPF Payables		2,143,282	3,875,488
	Add: Opening Payables to electricty, gas & water, debtors & Audit fees		697,749	716,355
	Less: Closing Payables to electricty, gas & water, debtors & Audit fees		757,655	697,749
	Add: Closing Advance to security deposit		1,576,827	2,161,827
	Less: Opening Advance to security deposit		2,161,827	2,161,827
	Less: Sample Expenses		1,020,458	1,509,911
	Less: Depreciation (PPE)		84,626,712	89,028,767
	Less: Depreciation (ROU)		4,622,265	4,622,264
	Total		**32,316,935**	**37,985,464**

FAMES & R * DHAKA BANGLADESH * CHARTERED ACCOUNTANTS

38.00 Disclosure as per requirement of schedule XI, Part II, Para 7 are given below:

Product Categories	Unit	Installed Capacity (Annual)	Actual Production During the period	% of Capacity utilization during the period
Tablet	Pcs.	454,500,000	262,187,695	57.69%
Capsules	Pcs.	331,280,000	179,678,411	54.24%
Liquid Syrup	Bottles	9,696,000	5,228,520	53.92%
SRS Saline	Pcs.	20,200,000	10,327,264	51.13%
Hand Sanitizer	Pcs.	4,242,000	2,125,232	50.10%
Total		**825,978,000**	**462,772,994**	**56.03%**

39.00 Disclosure as per requirement of Schedule-XI, Part-II, Note-5 of Para-3 of companies Act 1994

Employee Position (as on June 30, 2026)

Salary Range	Officer & Staff		Marketing Staff	Total Employee
	Factory	Head Office		
Below 6000	19	-	-	19
6000 or 6000 Above	99	39	127	265
Total	**118**	**39**	**127**	**284**

40.00 General

a) Audit Fee : Audit fee of Tk.3,50,000.00 represented only the audit fees and VAT thereon.

b) Capital Expenditure Contract

There is no capital expenditure contract has been made during the year.

c) Contingent Liabilities & Capital Commitments

There is no claim against the company not acknowledged debt and no un-availed credit facilities, other than those in the normal course of business, available to the company on June 30, 2026.

d) Comparative figures have been re-arranged where considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

e) Events After The Reporting Period: According to IAS-10, Events after the reporting period are those events, favourable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorised for issues. The Board of directors recommended 0.50% cash Dividend to all shareholders including directors, independent Director , Sponsor's and Generel shareholder's for the financial year 2025-2026 at the board meeting held on October 26, 2026. This dividend is subject to final approval by the shareholders at the forthcoming Annual General Meeting (AGM) of the company.

f) VAT: Company's Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non vatable items as per S.R.O No. 163-Law/2022/176-VAT, dated: June 01, 2022.

Note: Net vatable sales of taka 273,931,542 and Non-vatable sales of taka 98,218,209. The company has disclosed financial statements in net Sales of Tk.372,149,751.

41.00 Significant Deviation

During the period, turnover decreased compared to the corresponding year of the previous year. However, Earnings Per Share (EPS) has decreased due to decrease of net profit after tax. Net Operating Cash Flow per Share (NOCFPS) increase in the year mainly due to increase in net cash flows from operating activites. Despite this, Net Asset Value (NAV) increased, reflecting an improvement in shareholders' equity and overall financial position.

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Silco Pharmaceuticals Limited
Schedule of Property, Plant & Equipment
As at June 30, 2026

Annexure-A

Particulars	Cost			Rate of Dep. (%)	Depreciation			Written Down Value as at June 30, 2026
	Balance as on 1st July 2025	Addition during the year	Balance as on June 30, 2026		Balance as on 1st July 2025	Charge during the year	Balance as on June 30, 2026	
Land and Land Development	74,854,740		74,854,740	-	-	-	-	74,854,740
Building	1,110,510,672	41,548,599	1,152,059,271	2.50%	177,413,026	24,078,681	201,491,707	950,567,564
Plant & Machinery	1,417,444,058	9,941,962	1,427,386,020	10.00%	889,862,129	53,373,113	943,235,242	484,150,778
Electrical Equipment	25,994,860		25,994,860	10.00%	17,232,333	876,253	18,108,586	7,886,274
Electrical Installation	53,863,328		53,863,328	10.00%	39,716,228	1,414,710	41,130,938	12,732,390
Furniture & Fixture	22,317,093		22,317,093	10.00%	12,562,000	975,509	13,537,509	8,779,584
Office Equipment	10,551,192		10,551,192	10.00%	6,288,831	426,236	6,715,067	3,836,125
Computer	6,844,392		6,844,392	20.00%	4,947,868	379,305	5,327,173	1,517,219
Transformer	12,738,550		12,738,550	10.00%	10,013,270	272,528	10,285,798	2,452,752
Vehicles	41,300,815		41,300,815	10.00%	20,794,868	2,050,595	22,845,463	18,455,352
Air Condition	10,463,798		10,463,798	20.00%	7,410,907	610,578	8,021,485	2,442,313
Fire Extinguisher	6,990,180		6,990,180	20.00%	6,144,158	169,204	6,313,362	676,818
Balance as on June 30, 2026	**2,793,873,678**	**51,490,561**	**2,845,364,239**		**1,192,385,619**	**84,626,712**	**1,277,012,331**	**1,568,351,908**

Allocation of Depreciation	Rate (%)	Taka
Factory Expenses	94.00%	79,549,109
Administrative Expenses	2.00%	1,692,534
Selling & Distribution Expenses	4.00%	3,385,068
Total	**100%**	**84,626,712**

Silco Pharmaceuticals Limited
Schedule of Property, Plant & Equipment
As at June 30, 2025

Annexure-A

Particulars	Cost			Rate of Dep. (%)	Depreciation			Written Down Value as at June 30, 2025
	Balance as on 1st July 2024	Addition during the year	Balance as on June 30, 2025		Balance as on 1st July 2024	Charge during the year	Balance as on June 30, 2025	
Land and Land Development	74,854,740	-	74,854,740	-	-	-	-	74,854,740
Building	1,082,803,558	27,707,114	1,110,510,672	2.50%	153,901,511	23,511,515	177,413,026	933,097,646
Plant & Machinery	1,385,788,472	31,655,586	1,417,444,058	10.00%	832,390,920	57,471,209	889,862,129	527,581,929
Electrical Equipment	25,874,860	120,000	25,994,860	10.00%	16,261,897	970,436	17,232,333	8,762,527
Electrical Installation	53,863,328	-	53,863,328	10.00%	38,144,328	1,571,900	39,716,228	14,147,100
Furniture & Fixture	22,082,093	235,000	22,317,093	10.00%	11,484,039	1,077,962	12,562,000	9,755,093
Office Equipment	10,463,192	88,000	10,551,192	10.00%	5,816,066	472,765	6,288,831	4,262,361
Computer	6,278,712	565,680	6,844,392	20.00%	4,541,543	406,325	4,947,868	1,896,524
Transformer	12,738,550	-	12,738,550	10.00%	9,710,461	302,809	10,013,270	2,725,280
Vehicles	41,300,815	-	41,300,815	10.00%	18,516,430	2,278,439	20,794,868	20,505,947
Air Condition	10,463,798	-	10,463,798	20.00%	6,647,684	763,223	7,410,907	3,052,891
Fire Extinguisher	6,828,180	162,000	6,990,180	20.00%	5,941,973	202,185	6,144,158	846,022
Balance as on June 30, 2025	**2,733,340,298**	**60,533,380**	**2,793,873,678**		**1,103,356,852**	**89,028,767**	**1,192,385,619**	**1,601,488,059**

Allocation of Depreciation	Rate (%)	Taka
Factory Expenses	94.00%	83,687,041
Administrative Expenses	2.00%	1,780,575
Selling & Distribution Expenses	4.00%	3,561,151
Total	**100%**	**89,028,767**

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

Silco Pharmaceuticals Limited

Schedule of Right of Use Asset (ROU)
As at June 30, 2026

Annexure-B

Particulars	Cost				Rate of Dep. (%)	Depreciation				Written Down Value as at June 30, 2026
	Balance as on 1st July 2025	Addition during the year	Disposal	Balance as on June 30, 2026		Balance as on 1st July 2025	Charge during the year	Disposal	Balance as on June 30, 2026	
Office Rent (Head Office)	3,502,479			3,502,479	33.33	2,334,986	1,167,493		3,502,480	-
Office Rent (DO)	1,655,718			1,655,718	33.33	1,103,812	551,906		1,655,718	-
Office Rent (BDO)	1,034,823			1,034,823	33.33	689,882	344,941		1,034,823	-
Office Rent (BOG-DO)	2,260,850			2,260,850	33.33	1,507,234	753,617		2,260,850	-
Office Rent (KBO-DO)	1,241,788			1,241,788	33.33	827,858	413,929		1,241,788	-
Office Rent (MBO-DO)	1,241,788			1,241,788	33.33	827,858	413,929		1,241,788	-
Office Rent (NDO-DO)	1,783,080			1,783,080	33.33	1,188,720	594,360		1,783,080	-
Office Rent (CDO-DO)	1,146,266			1,146,266	33.33	764,178	382,089		1,146,266	-
Balance as on June 30, 2026	**13,866,793**	**-**	**-**	**13,866,793**		**9,244,528**	**4,622,265**	**-**	**13,866,793**	**-**

Silco Pharmaceuticals Limited

Schedule of Right of Use Asset (ROU)
As at June 30, 2025

Annexure-B

Particulars	Cost				Rate of Dep. (%)	Depreciation				Written Down Value as at June 30, 2025
	Balance as on 1st July 2024	Addition during the year	Disposal	Balance as on June 30, 2025		Balance as on 1st July 2024	Charge during the year	Disposal	Balance as on June 30, 2025	
Office Rent (Head Office)	3,502,479			3,502,479	33.33	1,167,493	1,167,493		2,334,986	1,167,493
Office Rent (DO)	1,655,718			1,655,718	33.33	551,906	551,906		1,103,812	551,906
Office Rent (BDO)	1,034,823			1,034,823	33.33	344,941	344,941		689,882	344,941
Office Rent (BOG-DO)	2,260,850			2,260,850	33.33	753,617	753,617		1,507,234	753,616
Office Rent (KBO-DO)	1,241,788			1,241,788	33.33	413,929	413,929		827,858	413,930
Office Rent (MBO-DO)	1,241,788			1,241,788	33.33	413,929	413,929		827,858	413,930
Office Rent (NDO-DO)	1,783,080			1,783,080	33.33	594,360	594,360		1,188,720	594,360
Office Rent (CDO-DO)	1,146,266			1,146,266	33.33	382,089	382,089		764,178	382,088
Balance as on June 30, 2025	**13,866,793**	**-**	**-**	**13,866,793**		**4,622,264**	**4,622,264**	**-**	**9,244,528**	**4,622,265**

FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH